Publications
Detailed Information
Phase I/II study of weekly Oraxol for the second-line treatment of patients with metastatic or recurrent gastric cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Keun-Wook | - |
dc.contributor.author | Lee, Kyung Hee | - |
dc.contributor.author | Zang, Dae Young | - |
dc.contributor.author | Park, Young Iee | - |
dc.contributor.author | Shin, Dong Bok | - |
dc.contributor.author | Kim, Jin Won | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Koh, Sung Ae | - |
dc.contributor.author | Yu, Kyung-Sang | - |
dc.contributor.author | Cho, Joo-Youn | - |
dc.contributor.author | Jung, Jin-A | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.date.accessioned | 2021-01-31T12:01:46Z | - |
dc.date.available | 2021-01-31T12:01:46Z | - |
dc.date.created | 2018-10-26 | - |
dc.date.created | 2018-10-26 | - |
dc.date.created | 2018-10-26 | - |
dc.date.created | 2018-10-26 | - |
dc.date.created | 2018-10-26 | - |
dc.date.issued | 2015-08 | - |
dc.identifier.citation | Oncologist, Vol.20 No.8, pp.896-897 | - |
dc.identifier.issn | 1083-7159 | - |
dc.identifier.other | 63448 | - |
dc.identifier.uri | https://hdl.handle.net/10371/173219 | - |
dc.description.abstract | Background. Oraxol consists of paclitaxel and HM30181A, a P-glycoprotein inhibitor, to increase the oral bioavailability of paclitaxel. This phase I/II study (HM-OXL-201) was conducted to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of Oraxol. In addition, we investigated the efficacy and safety of Oraxol as second-line chemotherapy for metastatic or recurrent gastric cancer (GC). Methods. In the phase I component, paclitaxel was orally administered at escalating doses (90, 120, or 150 mg/m(2) per day) with a fixed dose (15 mg/day) of HM30181A. Oraxol was administrated 6 times per cycle (days 1, 2, 8, 9, 15, and 16) every 4 weeks. In the phase II component, the efficacy and safety of Oraxol were evaluated. Results. In the phase I component, the MTD could not be determined. Based on toxicity and pharmacokinetic data, the RP2D of oral paclitaxel was determined to be 150 mg/m(2). In the phase II component, 4 of 43 patients (9.3%) achieved partial responses. Median progression-free survival and overall survival were 2.6 and 10.7 months, respectively. Toxicity profiles were favorable, and the most common drug-related adverse events (grade >= 3) were neutropenia and diarrhea. Conclusion. Oraxol exhibited modest efficacy and favorable toxicity profiles as second-line chemotherapy for GC. | - |
dc.language | 영어 | - |
dc.publisher | AlphaMed Press Inc | - |
dc.title | Phase I/II study of weekly Oraxol for the second-line treatment of patients with metastatic or recurrent gastric cancer | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1634/theoncologist.2015-0202 | - |
dc.citation.journaltitle | Oncologist | - |
dc.identifier.wosid | 000360973500013 | - |
dc.identifier.scopusid | 2-s2.0-84940037954 | - |
dc.citation.endpage | 897 | - |
dc.citation.number | 8 | - |
dc.citation.startpage | 896 | - |
dc.citation.volume | 20 | - |
dc.identifier.sci | 000360973500013 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Lee, Keun-Wook | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.contributor.affiliatedAuthor | Yu, Kyung-Sang | - |
dc.contributor.affiliatedAuthor | Cho, Joo-Youn | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | P-GLYCOPROTEIN INHIBITOR | - |
dc.subject.keywordPlus | LOW-DOSE PACLITAXEL | - |
dc.subject.keywordPlus | ORAL BIOAVAILABILITY | - |
dc.subject.keywordPlus | PLUS PACLITAXEL | - |
dc.subject.keywordPlus | SUPPORTIVE CARE | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | CISPLATIN | - |
dc.subject.keywordPlus | IRINOTECAN | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.